Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Seattle Genetics Gains After Analyst Raises Sales Estimate

Nov. 28 (Bloomberg) -- Seattle Genetics Inc., the maker of the recently approved cancer medicine Adcetris, rose the most in more than three months after an analyst said sales of the drug will be higher than previous estimates.

Seattle Genetics gained 7.6 percent to $16.16 at the close in New York, the biggest single-day increase since Aug. 19. The shares have risen 8.1 percent this year.

Adcetris was approved in August for patients with Hodgkin lymphoma for whom other therapies have failed, the first new medicine cleared by U.S. regulators for the disease since 1977. Jason Kantor, an RBC Capital Markets analyst in San Francisco, raised his fourth-quarter sales estimate for Adcetris 59 percent to $35 million after a survey of 100 doctors showed increased use of the drug.

“We believe the rapid uptake, high penetration rate, and potential for retreatment will position SGEN for multiple quarters of exceeding consensus expectations,” Kantor wrote yesterday in a note to clients.

To contact the reporter on this story: Ryan Flinn in San Francisco at rflinn@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.